We retrospectively reviewed the records of ovarian cancer at Women’s hospital, Zhejiang University School of Medicine between 2002.01.01 and 2016.12.31. The study was approved by the Ethical Committee of women’s hospital, Zhejiang University School of Medicine (IRB-20200230-R). Owing to the retrospective character and the difficulty of recalling all enrolled patients, informed consent was specifically waived by the ethics committee. All the researcher declared to protect patient data confidentiality and compliance with the Declaration of Helsinki. The enrolled patient should meet all the following inclusion criteria: (1) initial treatment was surgery including comprehensive surgical staging or cytoreductive surgery, followed by platinum-based chemotherapy in patients with stage Ic-IV, (2) histological diagnosis of EOC confirmed by Paraffin Section, (3) preoperative blood routine showed normal white blood cell and neutrophil count, (4) available serum CRP within 3 days before operation (preoperative) or within 7 days after operation (postoperative), and (5) available follow-up data of recurrence and death. Exclusion criteria included (1) primary other cancer; (2) the increase of CRP was caused by infection, connective tissue diseases or other inflammatory conditions, judged body temperature, clinical manifestation and auxiliary examination; (3) postoperative complications developed (including postoperative infection and massive bleeding); (4) the first dose of chemotherapy was delayed more than weeks after surgery; (5) only postoperative CRP results were available. Due to the retrospective character of the present study, patients with preoperative CRP results were included for evaluating the prognostic value of preoperative CRP, while patients with both preoperative and postoperative CRP results were included for perioperative CRP.
The clinical information of each selected patient was collected from the hospital database, and survival status was followed up by phone. The variables included age at diagnosis, histological type, FIGO stage, tumor grade, preoperative and postoperative serum CRP, preoperative serum CA125, postoperative residual tumor after primary surgery, chemotherapy sensitivity and the time of recurrence, death or last follow-up. Serum CRP was detected by immunoturbidimetry as part of the clinical routine management. Chemotherapy resistance was defined as having a time with recurrence of disease ≤6 months after completion of primary chemotherapy. Overall survival (OS) time was calculated as the interval between the date of primary surgery and the date of last follow-up or death. PFS was calculated as the interval from the date of primary surgery to the time of detected recurrence or progression.
The clinical information of each selected patient was collected from the hospital database, and survival status was followed up by phone. The variables included age at diagnosis, histological type, FIGO stage, tumor grade, preoperative and postoperative serum CRP, preoperative serum CA125, postoperative residual tumor after primary surgery, chemotherapy sensitivity and the time of recurrence, death or last follow-up. Serum CRP was detected by immunoturbidimetry as part of the clinical routine management. Chemotherapy resistance was defined as having a time with recurrence of disease ≤6 months after completion of primary chemotherapy. Overall survival (OS) time was calculated as the interval between the date of primary surgery and the date of last follow-up or death. PFS was calculated as the interval from the date of primary surgery to the time of detected recurrence or progression.
